Floatz logo

dl-3-n-butylphthalide

Moyamoya Disease

yuanli ZhaoPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Moyamoya Disease cohort.

Asset / SponsorPhaseRating
Erythropoietin Human Recombinant
Ajou University School of Medicine
Phase 1/2CCC

Same molecule, other indications

dl-3-n-butylphthalide is also rated in:

cerebral infarctionDormant
B
Indicative ·
60 / 100
View asset →
transient ischemic attackDormant
B
Indicative ·
57 / 100
View asset →
ischemic strokeDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →